Evidence map›Paper›PMID 34143379›Full record

ArticleMolecular imaging and biology2021

Preclinical Evaluation of

Kevin P Maresca, Jianqing Chen, Divya Mathur, Anand Giddabasappa, Adam Root, Jatin Narula, Lindsay King, David Schaer, Jonathan Golas, Keith Kobylarz and 12 more

Abstract read
In one paragraph

Article in Molecular imaging and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Imaging Immunotherapy.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Kevin P MarescaWorldwide Research, Development & Medicine, Pfizer Inc, New York, USA. kevin.maresca@pfizer.com.ORCID http://orcid.org/0000-0003-4420-1296
Jianqing ChenWorldwide Research, Development & Medicine, Pfizer Inc, New York, USA.
Divya MathurWorldwide Research, Development & Medicine, Pfizer Inc, New York, USA.
Anand GiddabasappaWorldwide Research, Development & Medicine, Pfizer Inc, New York, USA.
Adam RootWorldwide Research, Development & Medicine, Pfizer Inc, New York, USA.
Jatin NarulaWorldwide Research, Development & Medicine, Pfizer Inc, New York, USA.
Lindsay KingWorldwide Research, Development & Medicine, Pfizer Inc, New York, USA.
David SchaerWorldwide Research, Development & Medicine, Pfizer Inc, New York, USA.
Jonathan GolasWorldwide Research, Development & Medicine, Pfizer Inc, New York, USA.
Keith KobylarzWorldwide Research, Development & Medicine, Pfizer Inc, New York, USA.
Edward RosfjordWorldwide Research, Development & Medicine, Pfizer Inc, New York, USA.
Edmund KeliherWorldwide Research, Development & Medicine, Pfizer Inc, New York, USA.
Laigao ChenWorldwide Research, Development & Medicine, Pfizer Inc, New York, USA.
Sripad RamWorldwide Research, Development & Medicine, Pfizer Inc, New York, USA.
Eve H PickeringWorldwide Research, Development & Medicine, Pfizer Inc, New York, USA.
James S HardwickWorldwide Research, Development & Medicine, Pfizer Inc, New York, USA.
Paul A RejtoWorldwide Research, Development & Medicine, Pfizer Inc, New York, USA.
Amira HusseinInvicro, A Konica Minolta Company, New Haven, USA.
Ohad IlovichInvicro, A Konica Minolta Company, New Haven, USA.
Kevin StatonEvergreen Theragnostics, Jersey City, NJ, USA.
Ian WilsonImaginAb Inc., Inglewood, CA, USA.
Timothy J McCarthyWorldwide Research, Development & Medicine, Pfizer Inc, New York, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposeA sensitive and specific imaging biomarker to monitor immune activation and quantify pharmacodynamic responses would be useful for development of immunomodulating anti-cancer agents. PF-07062119 is a T cell engaging bispecific antibody that binds to CD3 and guanylyl cyclase C, a protein that is over-expressed by colorectal cancers. Here, we used PROCEDURES: NOD SCID gamma mice bearing human CRC LS1034 tumors were treated with four different doses of PF-07062119, or a non-targeted CD3 BsAb control, and imaged with

resultsThe results demonstrated substantial mean uptake of

conclusionImmune-imaging technologies for quantitative cellular measures would be a valuable biomarker in immunotherapeutic clinical development. We demonstrated a qualification of

Indexed as

Positron Emission Tomography Computed TomographyZirconiumAnimalsBiomarkersCell Line, TumorMiceMice, SCIDPositron-Emission TomographyReceptors, EnterotoxinT-LymphocytesBiomarkersReceptors, EnterotoxinZirconium89Zr-IAB22M2C PET imagingCD8 T cellGUCY2C bispecific antibodyImmuno-oncology

Identifiers

PMID34143379
PMCPMC8578158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.